We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Anaptysbio Announces Strategic Antibody Discovery Partnership with Celgene
News

Anaptysbio Announces Strategic Antibody Discovery Partnership with Celgene

Anaptysbio Announces Strategic Antibody Discovery Partnership with Celgene
News

Anaptysbio Announces Strategic Antibody Discovery Partnership with Celgene

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Anaptysbio Announces Strategic Antibody Discovery Partnership with Celgene"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

AnaptysBio, Inc. has announced a strategic partnership with Celgene Corporation to develop novel antibodies against multiple therapeutic targets.

Under this partnership, AnaptysBio is responsible for generating novel therapeutic antibodies to oncology and inflammation-related targets using its proprietary SHM-XEL platform.

Celgene will receive worldwide rights to develop and commercialize antibodies discovered by AnaptysBio under the terms of the partnership.

In addition to an upfront payment, AnaptysBio is due to receive preclinical and clinical milestone payments from Celgene, as well as royalties upon sales of each product derived from the partnership.

“AnaptysBio is uniquely positioned with a state-of-the-art antibody platform and an experienced antibody development team,” said Hamza Suria, AnaptysBio’s president and chief executive officer.

Suria continued, “We look forward to advancing novel antibody therapeutics with Celgene, in parallel with our internal pipeline programs.”

Advertisement